Oruka Therapeutics, Inc.
ORKA
Positions held
Your positionsORKA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Oruka Therapeutics operates in the biotechnology sector, which is known for its potential to innovate and address unmet medical needs, attracting significant investor interest.
- The company's market cap stands at approximately $5.31 billion, indicating a strong position in the market.
- Despite recent challenges, analysts have given a 'strong buy' recommendation with a target mean price of $155.
- Oruka Therapeutics has reported a consistent lack of revenue, with net income losses of -41.206 million in Q2 2026 and -31.82 million in Q1 2026.
- The company's operating income has been negative for multiple quarters, with -50.107 million in Q2 2026 and -36.434 million in Q1 2026.
- Current market signals indicate a 'Strong Sell' with a score of -16.00, reflecting negative trends and technical indicators.
Fundamentals
| Market cap | $5.12B | Enterprise value | $4.25B | Trailing P/E | — | Forward P/E | -27.00 |
| PEG | — | Price / book | 4.25 | Beta | -0.11 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -18.2% | ROA | -13.0% | Debt / equity | 0.00 |
| Current ratio | 38.51 | Free cash flow | -$65.03M | Analyst recommendation | strong_buy | Mean target | $155.00 |
| 52w high | $115.52 | 52w low | $24.31 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$41.2M | -$31.8M | -$29.6M | -$30.3M | -$24.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$50.1M | -$36.4M | -$34.4M | -$34.1M | -$28.4M | — |
Yearly (6y)
| 2025 | |
|---|---|
| Revenue | $0.0M |
| Op margin | — |
| Net income | -$105M |
| Gross margin | — |
| Gross profit | — |
| Operating income | -$122M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-24 · Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says
2026-09-24 · ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
2026-09-24 · What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders
2026-09-23 · The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
2026-09-23 · Update: Oruka Shares Fall Despite Deepening Week 28 Responses for ORKA-001
2026-09-23 · Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy
2026-09-23 · Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data
2026-09-23 · Oruka Therapeutics Reports Deepening Responses for ORKA-001 Through Week 28
2026-09-21 · Oruka Therapeutics Insider Sold Shares Worth $936,417, According to a Recent SEC Filing
2026-09-09 · Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
2026-08-28 · ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
Price (daily)
Full chart · RSI · MACD · patterns